Journal of Clinical Oncology
Articles in this Issue
Efficacy and safety of the DLL3 T-cell engager gocatamig in participants (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).
182 Background: Genitourinary neuroendocrine carcinomas (GU NEC), including small cell carcinoma of the bladder (SCCB) and...
Impact of tumor mutational burden on clinical outcomes in muscle-invasive bladder cancer patients treated with neoadjuvant chemotherapy.
814 Background: High tumor mutational burden (TMB) has been associated with poor response to cisplatin-based chemotherapy...
Radiographic recurrence patterns for prostate cancer with pathologic lymph node involvement following PSMA-PET and radical prostatectomy.
24 Background: Anatomic recurrence patterns for surgically resectable high-risk disease with regional node involvement on...
Survival outcomes in metastatic bladder cancer patients in the United States.
675 Background: Bladder cancer is the 10 th leading cause of cancer-related death...
Impact of positive ureteral margin on upper tract recurrence after radical cystectomy for bladder cancer.
872 Background: A positive ureteral margin has been considered a key risk factor for upper tract recurrence (UTR) followin...
Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC).
17 Background: VIR-5500, a dual-masked, PSMA-targeted bispecific T-cell engager, is designed to be specifically activated...
Artificial intelligence–based detection of treatment-emergent metastatic neuroendocrine carcinoma of prostate.
36 Background: Metastatic prostate carcinoma is a highly heterogeneous disease with a wide morphological spectrum and dise...
Circulating tumor (ct)DNA-guided adjuvant atezolizumab (atezo) in muscle-invasive bladder cancer (MIBC): Exploratory analysis of ctDNA dynamics in the IMvigor011 trial.
633 Background: In the randomized, double-blind, Phase 3 IMvigor011 trial (NCT04660344), ctDNA-guided adjuvant atezo led t...
Comparative outcomes of radiotherapy and interventional therapy for adrenal oligometastases: A multicenter retrospective study.
1 Background: Adrenal oligometastatic disease (OMD) represents an intermediate state between localized and systemic malign...
Metastatic progression and toxicity in high-risk clear cell renal cell carcinoma patients treated with adjuvant pembrolizumab at a tertiary care center.
471 Background: Pembrolizumab was approved in 2021 as adjuvant therapy for high-risk clear cell renal cell carcinoma (ccRC...
<i>ERBB3</i> -altered clinically advanced urothelial bladder cancer: Genomic landscape study and therapeutic possibilities.
799 Background: ERBB3 is often altered ( ERBB3 -alt) in advanc...
Healthy donor fecal microbiota transplantation combined with immunotherapy in metastatic renal cell carcinoma: Results from the phase I PERFORM trial.
559 Background: Despite advances with immune checkpoint inhibitors (ICI) and vascular endothelial growth factor (VEGF)–tar...
Ferroptosis suppression and its association with chemoradiotherapy resistance in muscle-invasive bladder cancer.
839 Background: Chemoradiotherapy (CRT) within trimodality therapy (TMT) offers a curative-intent, bladder-preserving opti...
Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.
344 Background: There are varying definitions of high-risk prostate cancer. The most commonly used is the NCCN definition...
Liquid biopsy-based detection of MTAP gene loss in non-muscle invasive bladder cancer.
844 Background: MTAP, located at chromosome 9p21.3 adjacent to CDKN2A/B, is frequently co-deleted with the CDKN2A in cance...
Succinate dehydrogenase B deficient renal cell carcinoma (RCC): A genomic landscape study.
551 Background: In addition to the association of SDHB genomic alterations (GA) wi...
Real-world (RW) outcomes associated with enzalutamide (enza) vs apalutamide (apa) in metastatic castration-sensitive prostate cancer (mCSPC): Analysis of United States (US) oncology electronic health record (EHR) data.
180 Background: RW data comparing first-line (1L) androgen receptor pathway inhibitors for mCSPC treatment (tx) are limite...
TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab vedotin (EV) + pembrolizumab (pembro).
TPS890 Background: Although first-line (1L) EV + pembrolizumab has improved outcomes for patients with la/mUC, most experi...
ResQ133A-NMIBC: A phase 1/2 clinical trial of intravesical recombinant mycobacterium bacillus Calmette-Guerin (rBCG) in participants living with non-muscle invasive bladder cancer eligible to receive conventional BCG.
TPS884 Background: Intravesical Bacillus Calmette-Guerin (BCG) is a standard and widely used therapy for non-muscle invasi...
Enfortumab vedotin and pembrolizumab (EVP) outcomes in patients (pts) with advanced urothelial carcinoma (aUC) and FGFR3 alterations: UNITE study analysis.
668 Background: EVP is the preferred 1 st line (1L) therapy for aUC pts and is inc...
ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial.
809 Background: Activating FGFR3 mutations and fusions occur in 10-20% of patients...
A randomized trial of neoadjuvant leuprorelin, darolutamide, or both prior to radical prostatectomy for intermediate- or high-risk prostate cancer.
TPS414 Background: While radical prostatectomy results in excellent survival in patients with low- and favorable intermedi...
Retrospective analysis of treatment responses to enfortumab vedotin combined with pembrolizumab (EVP) based on FGFR2/3 alterations in patients (pts) with advanced urothelial carcinoma (aUC).
688 Background: Reports vary as to the relationship between FGFR2/3 mutations (FGFR2/3m) and responses to EV in pts with a...
Switch androgen receptor pathway inhibitor strategies in metastatic castration-resistant prostate cancer: A meta-analysis of randomized trials.
198 Background: The optimal sequencing of therapy in metastatic castration-resistant prostate cancer (mCRPC) remains uncle...
Early peripheral blood neutrophil/lymphocyte ratio (NLR) dynamics to predict primary refractory disease in metastatic urothelial carcinoma (mUC) patients receiving PD1/L1 inhibitors.
793 Background: Early identification of refractory vs. sensitive disease may inform precision medicine in patients (pts) w...